Evidence map›Paper›PMID 40182293›Full record

ReviewFrontiers in microbiology2025

Advancements in the application and research of baculovirus vector vaccines for respiratory diseases in human.

Jinghua Yuan, Jingyu Chen, Qingzhi Zhao, Jialu Xu, Xianwei Li, Yijie Zhang, Hairun Li, Xintong Chen, Ling Zhao, Xiaofen Zhang and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jinghua Yuan *Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Jingyu Chen *Laboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Qingzhi ZhaoLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Jialu XuLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Xianwei LiLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Yijie ZhangLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Hairun LiLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Xintong ChenLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Ling ZhaoLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Xiaofen ZhangLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Hongyu LiLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
Keda ChenLaboratory of Artificial Organs and Computational Medicine in Zhejiang Province, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid spread of respiratory diseases, such as influenza, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Respiratory Syncytial Virus (RSV), poses significant challenges to global public health systems. Vaccination remains the most effective strategy to mitigate these threats. Baculovirus Expression Vector Systems (BEVS) have emerged as a promising platform for vaccine development, addressing key limitations of traditional methods, including complex production processes, lengthy timelines, and high costs. BEVS offers distinct advantages, such as enhanced efficacy, safety, cost-effectiveness, and scalability for large-scale manufacturing. This review highlights the application of BEVS in combating respiratory diseases by analyzing preclinical studies, clinical trials, and approved vaccines targeting these pathogens. It also examines recent advancements in BEVS technology, emphasizing its capacity to accelerate vaccine development and respond to emerging respiratory threats. By focusing on the synergy between BEVS and respiratory disease prevention, this review provides valuable insights to guide global vaccine innovation.

Indexed as

baculovirusclinical applicationpreclinical studyrespiratory diseasevaccine

Identifiers

PMID40182293
PMCPMC11965921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.